Matthew Sykes
Stock Analyst at Goldman Sachs
(3.29)
# 501
Out of 5,182 analysts
197
Total ratings
54.74%
Success rate
11.55%
Average return
Main Sectors:
Stocks Rated by Matthew Sykes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Maintains: Neutral | $7 → $5 | $10.60 | -52.83% | 4 | May 14, 2025 | |
| CTKB Cytek Biosciences | Maintains: Sell | $3.5 → $3 | $4.46 | -32.74% | 14 | May 12, 2025 | |
| TXG 10x Genomics | Maintains: Sell | $7.5 → $6.5 | $22.28 | -70.83% | 7 | May 12, 2025 | |
| BRKR Bruker | Maintains: Neutral | $50 → $45 | $36.53 | +23.19% | 5 | May 8, 2025 | |
| MYGN Myriad Genetics | Maintains: Buy | $14 → $8 | $4.83 | +65.63% | 12 | May 7, 2025 | |
| TWST Twist Bioscience | Maintains: Buy | $55 → $48 | $61.00 | -21.31% | 10 | May 6, 2025 | |
| SHC Sotera Health Company | Upgrades: Buy | $14 → $17 | $15.81 | +7.53% | 1 | May 5, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Neutral | $180 → $160 | $103.21 | +55.02% | 4 | May 2, 2025 | |
| NEO NeoGenomics | Maintains: Buy | $15 → $10 | $8.61 | +16.14% | 8 | Apr 30, 2025 | |
| RVTY Revvity | Maintains: Buy | $140 → $125 | $86.80 | +44.01% | 2 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $23 → $14 | $7.97 | +75.66% | 6 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $240 | $180.62 | +32.88% | 5 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $26 | $21.85 | +18.99% | 10 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $190 → $170 | $171.23 | -0.72% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $56 | $88.50 | -36.72% | 13 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $80 | $66.17 | +20.90% | 11 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.75 → $1.5 | $1.59 | -5.66% | 5 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $160 → $190 | $204.39 | -7.04% | 13 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $2.25 → $1.75 | $2.57 | -31.91% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $7 → $4.25 | $3.68 | +15.49% | 10 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $38 → $37 | $33.85 | +9.31% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $280 → $250 | $163.84 | +52.59% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $24 | $3.21 | +647.66% | 13 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,150 → $1,300 | $1,274.70 | +1.98% | 7 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $12 | $7.82 | +53.45% | 6 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $550 → $640 | $468.04 | +36.74% | 6 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $128 → $145 | $115.62 | +25.41% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $38.09 | - | 5 | Dec 7, 2023 |
Fortrea Holdings
May 14, 2025
Maintains: Neutral
Price Target: $7 → $5
Current: $10.60
Upside: -52.83%
Cytek Biosciences
May 12, 2025
Maintains: Sell
Price Target: $3.5 → $3
Current: $4.46
Upside: -32.74%
10x Genomics
May 12, 2025
Maintains: Sell
Price Target: $7.5 → $6.5
Current: $22.28
Upside: -70.83%
Bruker
May 8, 2025
Maintains: Neutral
Price Target: $50 → $45
Current: $36.53
Upside: +23.19%
Myriad Genetics
May 7, 2025
Maintains: Buy
Price Target: $14 → $8
Current: $4.83
Upside: +65.63%
Twist Bioscience
May 6, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $61.00
Upside: -21.31%
Sotera Health Company
May 5, 2025
Upgrades: Buy
Price Target: $14 → $17
Current: $15.81
Upside: +7.53%
ICON Public Limited Company
May 2, 2025
Maintains: Neutral
Price Target: $180 → $160
Current: $103.21
Upside: +55.02%
NeoGenomics
Apr 30, 2025
Maintains: Buy
Price Target: $15 → $10
Current: $8.61
Upside: +16.14%
Revvity
Apr 29, 2025
Maintains: Buy
Price Target: $140 → $125
Current: $86.80
Upside: +44.01%
Apr 29, 2025
Downgrades: Neutral
Price Target: $23 → $14
Current: $7.97
Upside: +75.66%
Apr 23, 2025
Maintains: Buy
Price Target: $260 → $240
Current: $180.62
Upside: +32.88%
Apr 17, 2025
Maintains: Buy
Price Target: $34 → $26
Current: $21.85
Upside: +18.99%
Mar 21, 2025
Downgrades: Neutral
Price Target: $190 → $170
Current: $171.23
Upside: -0.72%
Feb 21, 2025
Maintains: Buy
Price Target: $49 → $56
Current: $88.50
Upside: -36.72%
Feb 19, 2025
Maintains: Neutral
Price Target: $70 → $80
Current: $66.17
Upside: +20.90%
Feb 18, 2025
Maintains: Neutral
Price Target: $1.75 → $1.5
Current: $1.59
Upside: -5.66%
Jan 28, 2025
Maintains: Buy
Price Target: $160 → $190
Current: $204.39
Upside: -7.04%
Dec 5, 2024
Downgrades: Sell
Price Target: $2.25 → $1.75
Current: $2.57
Upside: -31.91%
Dec 5, 2024
Downgrades: Sell
Price Target: $7 → $4.25
Current: $3.68
Upside: +15.49%
Dec 5, 2024
Downgrades: Neutral
Price Target: $38 → $37
Current: $33.85
Upside: +9.31%
Nov 1, 2024
Maintains: Buy
Price Target: $280 → $250
Current: $163.84
Upside: +52.59%
Jul 9, 2024
Maintains: Buy
Price Target: $35 → $24
Current: $3.21
Upside: +647.66%
Jul 9, 2024
Maintains: Neutral
Price Target: $1,150 → $1,300
Current: $1,274.70
Upside: +1.98%
Jul 9, 2024
Maintains: Sell
Price Target: $32 → $12
Current: $7.82
Upside: +53.45%
Apr 10, 2024
Maintains: Buy
Price Target: $550 → $640
Current: $468.04
Upside: +36.74%
Dec 7, 2023
Maintains: Buy
Price Target: $128 → $145
Current: $115.62
Upside: +25.41%
Dec 7, 2023
Upgrades: Buy
Price Target: n/a
Current: $38.09
Upside: -